** Shares of Tylenol maker Kenvue KVUE.N rise 4.2% to $24.08 premarket
** KVUE says it earned a profit of 24 cents per share vs analysts' estimates of 23 cents per share - data compiled by LSEG
** Reports Q1 revenue of $3.74 billion vs estimates of $3.67 billion
** KVUE expects 2025 profit to remain flat year-over-year, anticipating higher costs from President Trump's tariffs on U.S. imports
** Co had previously forecast 2025 profit to be flat to 2% growth
** Separately, company appoints Amit Banati as chief financial officer, effective May 12
** Up to last close, stock has risen 8.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。